Navigation Links
Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
Date:4/22/2013

SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that Michael Narachi , president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years.

PhRMA represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

"PhRMA represents an industry dedicated to the noblest of missions:  Improving the health of patients all over the world," said Narachi. "I'm honored to join the board of PhRMA, and I'm looking forward to being a part of an organization whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients."

"I am pleased to welcome a respected industry leader, Mike Narachi , to PhRMA's Board of Directors," said PhRMA President and CEO John J. Castellani . "Mike's many years of experience in the biopharmaceutical sector make him an invaluable addition to our Board as we continue to fight for public policies that recognize the true value of innovative medicines for both patients and the American economy."

Narachi has served as Orexigen's President and Chief Executive Officer and a member of Orexigen's board of directors since March 2009.

Before joining Orexigen, Narachi served as Chairman, CEO and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009, and chairman of the board of director
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
3. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
4. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
5. Michael Berman Joins InspireMD Board
6. Secretary of Department of Environmental Protection, Michael Krancer, to Facilitate Networking Session at Pittcon 2013
7. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
8. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Sigma-Aldrich Elects Michael Marberry As Director
11. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), ... GHS Label Guide . To align chemical container labeling with OSHA’s updated Hazard ... of label components, an example of an accurate label, and pictogram uses and ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... March 21, 2011 Insmed Incorporated (Nasdaq: INSMD), a ... Drug Application (IND) to conduct a pivotal Phase 3 ... in nontuberculous mycobacteria (NTM) lung infections has been ...   In 2010, Insmed initially submitted a ...
... (LSE: SHP, Nasdaq: SHPGY ), the global ... alfa) in patients with Fabry disease, and VPRIV® (velaglucerase ... disease, at the 2011 American College of Medical Genetics, ... from March 16-20, 2011.   Data from ...
... 2011 Recent events in Japan have caused the ... radiation can be a cause for concern – especially ... targets rapidly proliferating cells of the body. Cells of ... tract are two such cell types. Damage to these ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 2Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 3Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 4Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 5Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... is not coming from the biotech industry or ... children,s hospital. Nationwide Children,s Hospital in Columbus, ... have partnered to create BioLinQ, a new biomedical ... for disease diagnosis and medical research. "Years ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
... with partners In2Tec Ltd (UK) and Gwent Electronic Materials Ltd, ... be easily separated by immersion in hot water. The work ... government,s Technology Strategy Board. The Challenge ... 100 million electronic units are discarded annually in the UK ...
Cached Biology News:NCH partners with Silicon Valley to market high-end diagnostic and medical research software 2Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: